Michael Maeng

Cardiologist, scientist, friend, husbond, father, cyclist

[Michael Maeng @MichaelMaeng1]

A new important paper on how to treat non-culprit lesions in patients with STEMI is now available in NEJM!

[Circulation @CircAHA]

NCL plaques and prognosis by clinical presentation @DavidErlinge @GreggWStone @FrobertOle
@ziadalinyc @GroThrane @MichaelMaeng1 https://t.co/I8n0Etz8MY

[Circulation @CircAHA]

Per-patient prevalence of high-risk vulnerable plaques was comparable in STEMI vs NSTEMI, as was the overall long-term incidence of non-culprit lesion-related & all MACE. @MichaelMaeng1 @GroThrane @DavidErlinge @GreggWStone @FrobertOle @ziadalinyc https://t.co/vNX1REUysk

[Michael Maeng @MichaelMaeng1]

@JACCJournals @CGyldenkerne An important paper when trying to understand the risk associated with T2DM. What comes first, the egg or the hen?

[Michael Maeng @MichaelMaeng1]

@TRUMP_ARMY_ No

[Michael Maeng @MichaelMaeng1]

@lucasaganronald Stupid question. Don't waste my time.

[Michael Maeng @MichaelMaeng1]

@lucasaganronald He is not underrated, just up against Vingo and Pogi🥶

[Michael Maeng @MichaelMaeng1]

@faustocoppi60 But Mads P was there🙂

[Michael Maeng @MichaelMaeng1]

@faustocoppi60 Last year Pogi lost big time due to suboptimal prep, this year its Jonas' turn. Next year?

[Michael Maeng @MichaelMaeng1]

@Frank_Huijbers VAR has destroyed my joy in watching football. We need to change the way it is used OR abandon VAR

[Michael Maeng @MichaelMaeng1]

@ncurzen Like Denmark in 1992, England will chock the world and win on Sunday, so you better find a replacement and be able to have Carlsberg🙂

[Cardiology Now News @CardioNowNews]

Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial
Written by
@ceciliabahit

Summary, analysis, and more #ADA2024 coverage below!
https://t.co/p84DqPXRg4
@CMichaelGibson

[Manan Pareek, MD, MSc, PhD, FACC, FAHA, FESC @MananPareekMD]

Thank you @PedersenTorp and Kristian for helping this newbie with the code and to @DLBHATTMD @mvaduganathan @TorBiering @ChristinaBFA @Pallisgaard_MD @MaBMortensen @MichaelMaeng1 @EmilFosb @gunngis @bonde_nissen @ThueOlsen and Lars, Christina, and Anna for perfecting the paper.

[JAHA @JAHA_AHA]

Procedural Outcomes After Percutaneous Coronary Interventions in Focal and Diffuse Coronary Artery Disease #AHAJournals @jeroen_sonck @MichaelMaeng1 @DMunhoz @belmontemarta1 https://t.co/9PDvlGvBKF

[Pernille Gro Thrane @GroThrane]

Excited to share our findings on 10-year mortality after STEMI, now in @JACCJournals
👉STEMI patients surviving the first 90 days have only mildly elevated mortality compared to a matched general population. https://t.co/a3SWkLsE0C
@MichaelMaeng1 #STEMI #cardiotwitter

[Michael Maeng @MichaelMaeng1]

The manuscript was also picked up by Dr. John Mandrola in his weekly podcast two days ago (https://t.co/QJegqA3w8i), and he was very positive with regards to both results and methodology.
@drjohnm

[Michael Maeng @MichaelMaeng1]

A great paper is out in JACC (https://t.co/BEArZYo5jv), where we shows that 90-day survivors following a STEMI has almost the same 10-year mortality as a matched general population. An important message to our patients!😍

[Michael Maeng @MichaelMaeng1]

An important paper in our understanding of why autoimmune diseases increase the risk of ischemic heart disease!

Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events https://t.co/sII1tDgHuk

[Michael Maeng @MichaelMaeng1]

@faustocoppi60 I think the last 2 stages sums it up pretty well🙂

[Michael Maeng @MichaelMaeng1]

@soudalquickstep Cheech and Chong